Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
Pharmather (PHRRF) Has Officially Broken Out.
Read Corporate Presentation Today.
Pharmather (PHRRF) which we gave a 'heads-up,' because looked like it was about to break...
Post Reverse Split Mania!
Now Wait a Minute, Aren't Stocks That do Reverse Splits Supposed go Down and Stay Down?
First our...
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the...
LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.
LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future
PharmaTher (PHRRF) Breaks Above Resistance.
We're now up 325% in just Under a Year. Last "big" News was Receiving a Priority Original Abbreviated New Drug Application,...
GeoVax (GOVX) Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
Ardelyx (ARDX) Firmly Above Resistance.
Were not traders and we don't do technical analysis, but we could see this coming from a mile away. Next stop $9.00...
Continued Strength at LQR House (LQR) Post-Reverse Split.
Like a Surprise Christmas Gift, LQR House has Gained Nearly Four-Fold (330%) Post Split. New Report out Tomorrow.
LQR House (LQR) +65%, Rebounding On New Clients Announcements.
The Liquor House Continues to Impress.
We called this the most interesting Company of 2023. While extreme volume...
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
